Hypoaldosteronism secondary prevention

Jump to navigation Jump to search

Hypoaldosteronism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hypoaldosteronism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypoaldosteronism secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hypoaldosteronism secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypoaldosteronism secondary prevention

CDC on Hypoaldosteronism secondary prevention

Hypoaldosteronism secondary prevention in the news

Blogs on Hypoaldosteronism secondary prevention

Directions to Hospitals Treating Hypoaldosteronism

Risk calculators and risk factors for Hypoaldosteronism secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]

Overview

Effective measures for the secondary prevention of hypoaldosteronism include liberal salt intake of 4gm/day (to increase plasma sodium concentration), decreasing potassium intake and avoidance of drugs that affects renin angiotensin aldosterone system (RAAS) such as ACE inhibitors, ARBs, potassium sparing diuretics and β-Adrenergic receptor blockers.

Secondary Prevention

References

  1. Ben Salem C, Badreddine A, Fathallah N, Slim R, Hmouda H (2014). "Drug-induced hyperkalemia". Drug Saf. 37 (9): 677–92. doi:10.1007/s40264-014-0196-1. PMID 25047526.
  2. Kuijvenhoven MA, Haak EA, Gombert-Handoko KB, Crul M (2013). "Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia". Int J Clin Pharm. 35 (6): 1099–104. doi:10.1007/s11096-013-9830-8. PMID 23974985.
  3. Indermitte J, Burkolter S, Drewe J, Krähenbühl S, Hersberger KE (2007). "Risk factors associated with a high velocity of the development of hyperkalaemia in hospitalised patients". Drug Saf. 30 (1): 71–80. PMID 17194172.

Template:WH Template:WS